PRECISION BIOSCIENCES INC
Precision BioSciences, Inc. (NASDAQ: PCBO) is a clinical-stage gene editing company developing in vivo genome editing therapies utilizing its proprietary ARCUS platform technology. The company's website is www.precisionbiosciences.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What PRECISION BIOSCIENCES INC does
In the company’s own words
Precision BioSciences, Inc. (NASDAQ: PCBO) is a clinical-stage gene editing company developing in vivo genome editing therapies utilizing its proprietary ARCUS platform technology. The company's website is www.precisionbiosciences.com.
The company focuses on translating genome editing capabilities into permanent genetic solutions for significant unmet medical needs in genetic and infectious diseases. ARCUS represents a differentiated approach to genome editing characterized by three unique properties: a distinctive staggered cut that produces defined outcomes through homology-directed repair, a compact size enabling delivery through lipid nanoparticles and adeno-associated viruses to diverse tissue types, and a single-component design requiring no guide RNA unlike competing CRISPR-based technologies.
Precision BioSciences operates two primary wholly-owned clinical programs. PBGENE-HBV is investigating a potentially curative treatment for chronic hepatitis B through elimination of covalently closed circular DNA and inactivation of integrated hepatitis B virus DNA, currently in Phase 1/2a trials across multiple global sites. PBGENE-DMD targets Duchenne muscular dystrophy through excision of specific dystrophin gene exons, with the Phase 1/2 FUNCTION-DMD study expected to generate initial data by year-end 2026. The company also maintains PBGENE-3243 for mitochondrial disease treatment, currently paused to prioritize lead programs.
Beyond internal development, Precision BioSciences has established partnerships advancing ARCUS technology across additional indications. iECURE is developing ECUR-506 for neonatal ornithine transcarbamylase deficiency with FDA Regenerative Medicine Advanced Therapy designation. The company previously held collaborations with Novartis for hemoglobinopathies, which terminated in January 2026, and maintains licenses with TG Therapeutics and Imugene for cell therapy applications.
As of December 31, 2025, the company employed 19 full-time employees holding Ph.D. or M.D. degrees. Precision BioSciences' intellectual property portfolio comprises licensed patents from Duke University and owned patent families covering core ARCUS platform technologies and in vivo gene editing applications, with protection extending across multiple jurisdictions including the United States, Europe, Japan, and other territories.
Company details
- Sector
- Healthcare
- Industry
- Biological Products
- Headquarters
- DURHAM, NC
- Fiscal year end
- May
- CIK
- 1357874
- SIC
- 2836
Financial performance, year by year
Fiscal 2019–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns PRECISION BIOSCIENCES INC — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · PRECISION BIOSCIENCES INC’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do PRECISION BIOSCIENCES INC and its peers compare on margins and cash generation over ten years?”
- “Where did five years of PRECISION BIOSCIENCES INC's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in PRECISION BIOSCIENCES INC's last four quarterly filings that the numbers alone won't show?”